Angela Dispenzieri

Research interests

Publications

• Amyloid nomenclature 2022: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee

  Amyloid · 2022 · https://doi.org/10.1080/13506129.2022.2147636

• ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2—Evidence Base and Standardized Methods of Imaging

  Circulation Cardiovascular Imaging · 2021 · https://doi.org/10.1161/hci.0000000000000029

• ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2—evidence base and standardized methods of imaging

  Journal of Nuclear Cardiology · 2019 · https://doi.org/10.1007/s12350-019-01760-6

• Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance

  New England Journal of Medicine · 2018 · https://doi.org/10.1056/nejmoa1709974

• International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease

  Blood · 2018 · https://doi.org/10.1182/blood-2018-07-862334

• International, evidence-based consensus diagnostic criteria for HHV-8–negative/idiopathic multicentric Castleman disease

  Blood · 2017 · https://doi.org/10.1182/blood-2016-10-746933

• Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial

  The Lancet · 2016 · 10.1016/s0140-6736(16)31594-x

• Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis

  Circulation · 2016 · https://doi.org/10.1161/circulationaha.116.021612

• Genotype and Phenotype of Transthyretin Cardiac Amyloidosis

  Journal of the American College of Cardiology · 2016 · https://doi.org/10.1016/j.jacc.2016.03.596

• Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System

  Journal of the American College of Cardiology · 2016 · 10.1016/j.jacc.2016.06.033

• Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma

  New England Journal of Medicine · 2014 · https://doi.org/10.1056/nejmoa1402551

• International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

  The Lancet Oncology · 2014 · https://doi.org/10.1016/s1470-2045(14)70442-5

• IMWG consensus on risk stratification in multiple myeloma

  Leukemia · 2013 · https://doi.org/10.1038/leu.2013.247

• Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients

  Leukemia · 2013 · 10.1038/leu.2013.313

• New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes

  Journal of Clinical Oncology · 2012 · https://doi.org/10.1200/jco.2011.37.7614

• Clonal competition with alternating dominance in multiple myeloma

  Blood · 2012 · https://doi.org/10.1182/blood-2012-01-405985

• Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis

  Leukemia · 2012 · https://doi.org/10.1038/leu.2012.100

• Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements

  Journal of Clinical Oncology · 2012 · 10.1200/jco.2011.38.5724

• Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

  Leukemia · 2011 · https://doi.org/10.1038/leu.2011.196

• Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines

  Mayo Clinic Proceedings · 2009 · 10.4065/mcp.2009.0603

• Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study

  Blood · 2009 · 10.1182/blood-2008-12-194241

• International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders

  Leukemia · 2008 · 10.1038/leu.2008.307

• Promiscuous Mutations Activate the Noncanonical NF-κB Pathway in Multiple Myeloma

  Cancer Cell · 2007 · 10.1016/j.ccr.2007.07.003

• Improved survival in multiple myeloma and the impact of novel therapies

  Blood · 2007 · https://doi.org/10.1182/blood-2007-10-116129

• Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma

  New England Journal of Medicine · 2007 · 10.1056/nejmoa070389

• Prevalence of Monoclonal Gammopathy of Undetermined Significance

  New England Journal of Medicine · 2006 · https://doi.org/10.1056/nejmoa054494

• Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance

  Blood · 2005 · 10.1182/blood-2005-03-1038

• Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma

  Blood · 2005 · 10.1182/blood-2005-07-2817

• Serum Cardiac Troponins and N-Terminal Pro-Brain Natriuretic Peptide: A Staging System for Primary Systemic Amyloidosis

  Journal of Clinical Oncology · 2004 · 10.1200/jco.2004.03.029

• POEMS syndrome: definitions and long-term outcome

  Blood · 2003 · 10.1182/blood-2002-07-2299

• Review of 1027 Patients With Newly Diagnosed Multiple Myeloma

  Mayo Clinic Proceedings · 2003 · https://doi.org/10.4065/78.1.21

Current projects

No projects listed.